Low-Affinity Anti-CD3 Antibodies for Controlled T Cell Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing bispecific antibodies for cancer immunotherapy face challenges in achieving consistent T cell activation and efficacy while minimizing toxicity and improving pharmacokinetic properties, particularly due to inconsistent CD3 binding affinities and resulting cytotoxic responses.
Innovation Solution
Development of anti-CD3 antibodies with weak or no detectable binding affinity, designed to target T cells for controlled cytotoxicity and improved pharmacokinetics, utilizing specific amino acid sequences and modifications to achieve selective T cell activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high affinity anti-CD3 antibodies are used to stimulate T cell activation, then T cell activation efficacy is improved, but toxicity and side effects increase
Solution Approach 1:
The patent applies parameter changes by systematically modifying the affinity of the anti-CD3 binding arm across multiple embodiments. Different bispecific antibodies are designed with varying KD values (from high affinity ~10^-9 M to low affinity >10^-6 M) to evaluate the relationship between binding affinity and both T cell activation efficacy and toxicity. This parameter optimization allows identification of the optimal affinity range that maintains therapeutic efficacy while minimizing adverse effects.
Solution Approach 2:
The patent implements partial action by using low affinity binding (KD > 10^-6 M) in certain embodiments where the binding is intentionally kept below detectable levels in vitro. This partial binding approach is sufficient to achieve the desired therapeutic effect in vivo through avidity mechanisms, while avoiding the excessive toxicity associated with high affinity binding. The partial action principle is applied by designing antibodies that bind weakly to CD3 but still effectively activate T cells against tumor targets.
2Reliability
If high affinity CD3 binding is achieved, then T cell activation is enhanced, but pharmacokinetic properties deteriorate
Solution Approach 1:
The patent applies parameter changes by optimizing the binding affinity parameter to achieve the optimal balance between T cell activation and pharmacokinetic properties. By systematically varying the KD value across different antibody embodiments, the patent identifies that lower affinity (KD > 10^-6 M) results in improved in vivo persistence and reduced clearance rates, thereby enhancing pharmacokinetic properties while maintaining therapeutic efficacy through avidity-driven mechanisms.
3Measurement precision
If affinity maturation is used to increase binding specificity, then binding affinity is improved, but detectable binding becomes excessive
Solution Approach 1:
The patent applies the inversion principle by reversing the conventional approach to affinity maturation. Instead of increasing binding affinity through traditional affinity maturation techniques, the patent deliberately reduces affinity to below detectable levels (KD > 10^-6 M) in certain embodiments. This inverted approach maintains binding specificity through structural complementarity while avoiding excessive detectable affinity, thereby achieving the desired therapeutic effect with reduced toxicity.
4Reliability
If consistent T cell activation is achieved through high affinity binding, then efficacy is improved, but cytotoxic responses become uncontrolled
Solution Approach 1:
The patent applies parameter changes by optimizing the binding affinity parameter to control the degree of T cell activation. By using low affinity binding (KD > 10^-6 M), the patent achieves consistent T cell activation through avidity mechanisms while preventing excessive cytotoxic responses. The lower affinity allows for more controlled and sustained activation compared to the burst cytotoxicity caused by high affinity binding, thereby improving the therapeutic index.
Data Source
AI summary
The present invention provides antibodies that bind to CD3 with weak or no detectable binding affinity and methods of using the same. According to certain embodiments, the antibodies of the invention bind human CD3 with low affinity and induce human T cell proliferation and hence induce T cell-mediated killing of tumor cells with high efficacy. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3 with weak or no detectable binding affinity in an in vitro assay, and a second antigen-binding molecule that specifically binds human tumor-associated antigen. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing target antigen, such as PSMA. The antibodies and bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial. For antibodies of the invention are useful for the treatment of various cancers or other diseases where immunotherapy, including effector cell immunomodulation, is warranted.